Clinical Trial Update: A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy [Phase 3]

View source ↗

Summary

Phase 3 study evaluating REGN5713-5715 for reducing signs and symptoms of ocular allergy in adults with birch pollen allergy (allergic conjunctivitis).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis
• Birch Pollen Allergy

Drugs mentioned

• REGN5713-5715

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Allergic Conjunctivitis | Phase 3 | Status: COMPLETED